The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study.
Brain-derived neurotrophic factor (BDNF)
First-episode schizophrenia
Nerve growth factor (NGF)
Peripheral biomarker
Prevention
Relapse
Journal
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
09
09
2021
revised:
01
02
2022
accepted:
03
02
2022
pubmed:
27
2
2022
medline:
13
4
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Neurotrophins have been proposed to be involved in biological mechanisms which might underlie different clinical outcomes in schizophrenia. The aims of the present study were to examine the BDNF/NGF plasma levels in a cohort of first-episode schizophrenia (FES) patients in remission as potential biological predictors of relapse; to study the associations between these neurotrophins and the symptomatology severity through different stages after a FES in two independent cohorts. 2EPs-Cohort: 69 first-episode in clinical remission were included. BDNF/NGF plasma levels and symptom severity were measured at enrollment and at 3-year or at the time of the second episode/relapse. FLAMM-PEPs-Cohort: 65 first-episodes were also included. BDNF/NGF and symptom severity were obtained at enrollment and 2-year follow-up. Symptomatology was assessed with the Marder-PANSS-Factor scores. Plasma neurotrophins did not differ significantly over time and neither BDNF/NGF were predictors of relapse. Besides, in remission stages, baseline BDNF levels showed significant correlations with both positive and negative symptoms (p<0.05); NGF, with negative symptomatology (p<0.01). Similarly, in the FLAMM-PEPs-Cohort, baseline BDNF/NGF levels showed significant correlations with negative symptoms (and not positive symptomatology) at follow-up (p<0.05). In both cohorts, lower levels correlated with higher symptom severity. Findings did not support a role for BDNF/NGF plasma levels as biomarkers of relapse in FES patients. Nevertheless, baseline BDNF/NGF may lead to be considered potentially useful biomarkers of long-term severity in schizophrenia and of the underlying illness traits, specially of negative symptomatology severity. More longitudinal studies in FES samples and adding a control group are warranted to replicate these findings.
Identifiants
pubmed: 35219096
pii: S0924-977X(22)00128-6
doi: 10.1016/j.euroneuro.2022.02.003
pii:
doi:
Substances chimiques
Biomarkers
0
Brain-Derived Neurotrophic Factor
0
NGF protein, human
0
BDNF protein, human
7171WSG8A2
Nerve Growth Factor
9061-61-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-117Investigateurs
S Amoretti
(S)
C Morén
(C)
E Urbiola
(E)
J González-Peñas
(J)
A Roldán
(A)
A Catalán
(A)
I González-Ortega
(I)
A Toll
(A)
T Legido
(T)
L Sanchez-Pastor
(L)
M Dompablo
(M)
E Pomarol-Clotet
(E)
Landín-Romero R
(LR)
A Butjosa
(A)
E Rubio
(E)
None Lorente-OmeñacaR
M Ribeiro
(M)
I López-Torres
(I)
L León-Quismondo
(L)
J Nácher
(J)
F Contretas
(F)
A Lobo
(A)
M Gutiérrez-Fraile
(M)
P A Sáiz
(PA)
Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Conflict of Interest Dr. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda. Pilar A Sáiz, has been a consultant to and/or has received honoraria or grants from Adamed, CIBERSAM, European Comission, Government of the Principality of Asturias (PCTI-2018–2022 IDI/2018/235), Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional sobre Drogas and Servier. The rest of authors have declared that there are no conflicts of interest in relation to the subject of this study.